| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/prediction-buying-biotech-stock-today-could-set-you-life","as_of":"2026-04-13T10:26:04.867531+00:00","canonical_url":"https://www.fool.com/investing/2026/04/13/prediction-buying-this-biotech-stock-today-could-s/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/prediction-buying-biotech-stock-today-could-set-you-life","article_chars":4602,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_f68a309654f005d7","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/13/prediction-buying-this-biotech-stock-today-could-s/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-13T16:03:14.294731+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsMirum Pharmaceuticals already markets three therapies.","fetched_title":"Prediction: Buying This Biotech Stock Today Could Set You Up for Life | Nasdaq","final_url":"https://www.nasdaq.com/articles/prediction-buying-biotech-stock-today-could-set-you-life","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/prediction-buying-biotech-stock-today-could-set-you-life","source_event_id":"evt_48ce1b77f119","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"49beef9e149158c5","kind":"unusual_volume","published_at":"2026-04-13T10:03:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2025","fourth quarter of 2025","2026","Q2 2026","second half of this year","Q4 (year not explicitly stated)","first half of 2027","2027","April 13, 2026"],"entities":[{"asset_class":"equity","name":"Mirum Pharmaceuticals","relevance":"high","symbol":"MIRM","type":"company"},{"asset_class":"other","name":"Motley Fool","relevance":"medium","symbol":"","type":"publisher"}],"event_type":"other","information_gaps":["Signal type is discovery_unusual_volume_delta, but the provided text contains no trading volume figures, no baseline/average volume, and no volume ratio.","No explicit statement confirms whether any unusual volume is driven by news versus being unexplained.","The excerpt does not specify the year for items described as \u201csecond half of this year\u201d and \u201cfourth quarter\u201d (only Q2 2026 and first half of 2027 are explicit).","No direct catalyst is tied to unusual volume; the only potential catalysts mentioned are upcoming clinical readouts and sales/FCF developments."],"key_facts":["Mirum markets three therapies: Livmarli, Ctexli, and Cholbam.","Livmarli is approved in the U.S. and Europe for ALGS and PFIC.","Ctexli is approved in the U.S. for CTX.","Cholbam is approved in the U.S. for BASD.","Net product sales jumped 50% year over year in the fourth quarter of 2025.","Livmarli sales rose 69% to $360 million in the fourth quarter of 2025.","Mirum generated positive free cash flow in 2025.","The article states increased R&D spending will make free cash flow negative in the current year, with management expecting a return to positive free cash flow in 2027.","Mirum plans four pivotal readouts over the next 18 months.","Top-line data for volixibat in PSC is expected in Q2 2026 (Phase 3).","Phase 3 data for brelovitug in HDV is expected in the second half of this year (year not explicitly stated in the excerpt).","Livmarli Phase 3 results for cholestatic pruritus are expected in Q4 (year not explicitly stated).","Top-line results for volixibat in PBC are expected in the first half of 2027.","The article states peak sales estimates for pipeline candidates top $4 billion.","The article states Mirum\u2019s market cap is about $5.8 billion and uses an average biotech P/S ratio of 6.4 to estimate a potential value of about $26 billion if therapies fulfill potential."],"numeric_claims":[{"label":"Stock performance (12 months)","value":"more than 120% (as stated)"},{"label":"Net product sales growth (Q4 2025)","value":"50% year over year"},{"label":"Livmarli sales growth (Q4 2025)","value":"69%"},{"label":"Livmarli sales (Q4 2025)","value":"$360 million"},{"label":"Peak sales estimates for pipeline candidates","value":"top $4 billion"},{"label":"Market cap","value":"~$5.8 billion"},{"label":"Average biotech P/S ratio used","value":"6.4"},{"label":"Implied value estimate","value":"~$26 billion"}],"primary_claim":"Mirum Pharmaceuticals plans to report four pivotal clinical readouts over the next 18 months, with specific Phase 3 data timing starting in Q2 2026, and positive results could materially benefit the stock.","relevance_score":0.35,"sentiment":"positive","source_quality":"high","summary":"The article discusses Mirum Pharmaceuticals (NASDAQ: MIRM), highlighting strong recent sales growth and upcoming clinical readouts that could drive stock gains if results are positive. It does not provide any specific unusual trading volume ratio or confirm a volume-related catalyst.","topics":["biotech","clinical trials","Phase 3 readouts","pipeline","sales growth","valuation discussion"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsMirum Pharmaceuticals already markets three therapies.","tickers":[],"title":"Prediction: Buying This Biotech Stock Today Could Set You Up for Life","url":"https://www.fool.com/investing/2026/04/13/prediction-buying-this-biotech-stock-today-could-s/"}... |